Navigation Links
Phase Genomics Announces the Commercial Availability of ProxiMeta™ Hi-C
Date:5/16/2017

Seattle-based Phase Genomics announced today the general availability of its new ProxiMeta™ Hi-C metagenomic deconvolution service. ProxiMeta enables researchers to obtain complete, distinct genomes from microbiome samples easily and affordably—without culturing or high-molecular-weight DNA extraction—speeding research insights at lower cost.

“We’re very excited about the commercial launch of our newest service for metagenomic assembly,” said Dr. Ivan Liachko, CEO and Co-founder of Phase Genomics. “ProxiMeta will help researchers answer longstanding, fundamental questions about their microbial samples. We give customers a way to explore the dark matter of the microbiome by quickly assembling the many genomes contained in a sample, leading to answers they could not have found otherwise.”

Microbial communities are typically made up of many different species living together. Standard methods for sequencing these communities mix together information from all the microbes in the sample. The result is a hodgepodge of genes that is challenging to analyze, and unknown species in the sample are difficult to discover. The innovative ProxiMeta Hi-C method reveals which DNA sequences originated in the same cell, enabling the assembly of whole genomes from mixed microbial samples in their natural state.

"Phase Genomics' ProxiMeta Hi-C solution makes innovative use of Illumina reads to conduct metagenomic deconvolution and extract more complete sequence information from mixed microbiome samples,” said Gary Schroth, PhD, Vice President of Genomics Development and Distinguished Scientist for Illumina. “This technology promises to open many new metagenomic applications and we’re excited to see it come to market."

CLEAR RESEARCH BENEFITS

By combining Hi-C proximity data and metagenomic sequencing, ProxiMeta delivers benefits not available from other methods.

  • Clarity. Gain a more detailed view of microbial communities using the only method that moves straight from a raw sample to scores, or hundreds, of individual, reference-quality genomes.
  • Simplicity. Simply collect and send in a microbial sample. No culturing is required, saving time and cost.
  • Velocity. With publication-ready data typically available in 30 days, researchers can find and publish new insights faster.

"ProxiMeta Hi-C facilitates the cultivation-independent assembly of bacterial genomes present in complex microbial communities. Of particular interest is its potential to associate plasmids with their host genomes. Without having to culture individual isolates, ProxiMeta offers a new approach to examine the reservoirs of mobile genetic elements that carry genes of interest, such as toxin or antimicrobial resistance genes,” said Professor Eva Top, Bioinformatics and Computational Biology Graduate Program Director at the University of Idaho.

A SIMPLE PROCESS

ProxiMeta Hi-C is based on capturing physical DNA proximity with in vivo Hi-C. This allows sequences from the same species and/or strain to be grouped, yielding a large number of genomes for rare, unculturable, and novel microbes. The ProxiMeta Hi-C service is a straightforward process for researchers:

  • Researchers contact Phase Genomics to obtain a quote
  • Researchers collect a raw sample (for example, a fecal or soil sample) and send it to Phase Genomics
  • Phase Genomics processes the sample, providing shotgun sequencing, assembly, and metagenomic deconvolution
  • Phase Genomics delivers the resulting genomes, along with supplementary figures and reports, to a secure online location for customer access, typically within 30 days of receiving a sample

Interested parties can learn more about ProxiMeta and other Phase Genomics services by visiting the Phase Genomics table at the Sequencing, Finishing and Analysis in the Future (SFAF) conference May 16-18, or at http://www.phasegenomics.com.

Read the full story at http://www.prweb.com/releases/2017/05/prweb14333703.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
2. Former FDA Official to Conduct Popular ComplianceOnline Seminar on FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials
3. Phase Genomics and Phyzen Co., Ltd. Announce Korean Distribution Partnership
4. Histogen and Worcester Polytechnic Institute Receive Phase II NSF Award to Develop Unique Wound Treatment
5. 2-Day Seminar FDAs GMP Expectations for Phase I and First-in-Man Clinical Trials by Ex-FDA Official (Tampa, FL, United States - May 18-19, 2017) - Research and Markets
6. Maxwell Biotech Venture Funds Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
7. Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis
8. RepliCels Phase 1 Clinical Trial for Hair Loss Succeeds in Meeting Primary Endpoints
9. Phase Genomics Proximo Hi-C Technology Featured in Nature Genetics
10. SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients
11. OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... 2017 , ... Vortex Biosciences , provider of circulating tumor cell (CTC) ... cells using Vortex microfluidic technology ” in Nature Precision Oncology on May 8th. ... Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. The publication ...
(Date:5/23/2017)... Switzerland (PRWEB) , ... May 23, 2017 , ... ... forces machine manufacturers to re-engineer their control technology again and again. METTLER TOLEDO ... problem for machine manufacturers. The videos illustrate how integration of the ACT350 into ...
(Date:5/21/2017)... ... May 20, 2017 , ... ... the lengthy trial and error process by finding the right antidepressant faster. ... strengthen the doctor-patient relationship through a personalized approach to treatment. , ...
(Date:5/18/2017)... ... May 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great Point Partners ... to grow. CSM has doubled in size over the past six months with ... strategy. , Roger Gasper joins CSM as Chief Financial Officer. Roger has over ...
Breaking Biology Technology:
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
Breaking Biology News(10 mins):